End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
6.24 CNY | -1.42% | -3.26% | -13.21% |
Apr. 26 | Winning Health Technology Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 19 | UBS Upgrades China's 2024 GDP Growth Forecast | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 59% by 2026.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The group's high margin levels account for strong profits.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The firm trades with high earnings multiples: 24.4 times its 2024 earnings per share.
- With an enterprise value anticipated at 3.65 times the sales for the current fiscal year, the company turns out to be overvalued.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: IT Services & Consulting
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-13.21% | 1.87B | C- | ||
-14.01% | 192B | A- | ||
+1.48% | 169B | B+ | ||
+4.29% | 157B | B- | ||
+7.00% | 103B | A- | ||
+13.18% | 82.82B | A- | ||
+38.52% | 82.8B | C- | ||
-5.04% | 73.21B | A | ||
-21.10% | 51.79B | C | ||
-8.25% | 44.01B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300253 Stock
- Ratings Winning Health Technology Group Co., Ltd.